<DOC>
	<DOCNO>NCT02205255</DOCNO>
	<brief_summary>A second sub-analysis BACE trial include detail cost-effectiveness study .</brief_summary>
	<brief_title>BACE Trial Substudy 2 - FarmEc Substudy</brief_title>
	<detailed_description>Our multicenter randomize trial execute one country provide excellent tool precise health economic assessment . In first approach , rough estimate saving direct cost entire study cohort make take account Flemish average cost single hospitalization day respiratory ward , day intensive care , emergency visit , home physician contact antibiotic-steroid course . A detailed cost-effectiveness cost-utility analysis 3 9 month interval perform case significant clinical benefit find favor active treatment . For purpose medical resource use data collect retrospectively via hospital invoice ( direct cost include drug , physician visit , laboratory test , technical exam , medical imaging , hospital stay ) also prospectively via patient diary , cover direct indirect cost entire outpatient period , link EQ5D score . Patient give inform consent additional clinical evaluation , invoice collect . However , individual patient still opt analysis ( sub-study ) participate medical intervention study ( main study ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Established diagnosis COPD medical doctor ( base clinical history OR pulmonary function test ) Smoking history least 10 packyears ( 10 packyears define 20 cigarette day 10 year , 10 cigarette day 20 year , etc . ) Current hospitalization potential infectious AECOPD treat standard therapy History least one exacerbation last year ( prior current hospital admission ) systemic steroid and/or antibiotic take ECG admission Mechanical noninvasive ventilation moment randomization ( D1 ) Long QT interval ECG ( QTc &gt; 450msec male &gt; 470msec female ) History lifethreatening arrhythmias Myocardial infarction ( NSTEMI STEMI ) less 6 week start study drug Unstable angina pectoris acute myocardial infarction ( NSTEMI STEMI ) admission Drugs high risk long QT interval torsade de pointes ( amiodarone , flecainide , procainamide , sotalol , droperidol , haldol , citalopram , macrolides ) Documented uncorrected severe hypokalemia ( K+ &lt; 3.0 mmol/L ) hypomagnesemia ( Mg2+ &lt; 0.5 mmol/L ) Chronic systemic steroid ( &gt; 4 mg methylprednisolone /day â‰¥ 2 month ) Actual use macrolides least 2 week Allergy macrolides Active cancer treatment Life expectancy &lt; 3 month Pregnant breastfeeding subject . Woman childbearing potential must pregnancy test perform negative result must document start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AECOPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Acute exacerbation</keyword>
	<keyword>Hospitalization</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Macrolides</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Placebo</keyword>
	<keyword>Economic Impact</keyword>
	<keyword>Cost-effectiveness</keyword>
	<keyword>EQ5D</keyword>
</DOC>